Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Presidential profit? Stocks and elections


Bookmark and Share
by Jim Stack, editor Investech Market Analyst

Jim StackWhat lies ahead in 2012? That’s the big question, and the fact that we’re approaching a Presidential Election likely improves the chances that this will be a good year for the stock market.

Historically, there has been a clear visible link between the Presidential Election Cycle and Wall Street. Below, we look at the correlation between cycles in the stock market and the 4-year election cycle.

Off-election years are often preceded by bear markets or stagnant growth and typically provide some of the best buying opportunities for stocks.  

However, one rarely sees the market swooning in the 12 to 18 months leading up to a Presidential Election – 1960 and 2008 are the notable exceptions.

If you think about it, this relationship makes sense.  Any politician worth his salt knows that you should try to get bad news and bear markets out of the way as quickly as possible after taking office.  

That way, the economy and the stock market can get back on track and be ticking along smoothly when it’s time to run for re-election.  

You rarely see Washington passing controversial tax hikes or legislation once the Presidential campaigns get rolling in earnest, and even the Federal Reserve, which is not supposed to be politically influenced, is reluctant to rock the boat by significantly increasing interest rates during an election year.

Historically (since 1941), the first two years after a Presidential Election have the lowest performance, with average annual gains less than 5.5%.
Advertisement
Banner


Year 3, as politicians start gearing up for re-election, is usually the best on Wall Street by a wide margin. With an average gain of 17.3%, it more than doubles the return of the other three years.  

Presidential Election years tend to be more moderate, but historically are still the second most profitable in the cycle. Before the financial crisis, the average annual gain for election years was 8.9%; however, the 38% drop in the S&P 500 in 2008 reduced the long-term average to 6.2%.

The current 2009-2012 Presidential Election cycle is anything but “average.”  After the 2008 debacle, the bull market recovery came early.  

Years 1 and 2 were far stronger than usual, which likely stole performance from Year 3. Consequently, 2011 fell far short of expectations, ending with 0% gain in the S&P 500 after it suffered a sharp bearish contraction mid-year.  

Although the progression up to now has been atypical, what are the odds that this election year will be closer to the norm?  In seeking the answer we looked back at prior cycles, where historical precedent has not always prevailed.

Election years can be volatile (what years can’t), but they rarely end with big losses for investors.  

We looked at every Presidential Election year since 1900 along with the gain or loss in the DJIA (excluding dividends). Note that: 
  • The average gain for these 28 election years is 7.3%, which is equivalent to the average annual market gain taking all 112 years into consideration.  However, if we exclude 2008, which was the worst Presidential Election year in over a century, the election year average jumps to 8.8%. 

  • Two-thirds of the periods were positive for the market, while years with major losses were rare. 

  • Election years that showed double-digit gains outnumber those with double-digit losses by nearly 3:1 – and only one of those double-digit losses occurred after 1940. That was in 2008 when the economy was deep in recession at election time (which was also the case in 1960), and it cost the incumbent party dearly at the polls.
Our study also revealed another secret in Presidential Election years… the market often rallies in the second half of the year. 
  • In all but six election years, the DJIA either hit a new yearly high, or came within 5% of the year’s high, in the 4th quarter. 

  • There have been only five elections where the market dropped to a new yearly low in the 4th quarter, and three occurred during major recessions – 1920, 1932 and 2008. 

  • In 2004, the 4th quarter saw both extremes.  The low was hit in October, and the DJIA rallied to its high for the year in December.
Looking at 2012, the year has started off with good news on the economic front – leading data is improving along with confidence and recession fears are receding.  

Also, the technical picture is more encouraging, with stronger market breadth and the disappearance of bearish distribution.

In our opinion, this evidence, along with the Presidential Election Cycle, reduces the chance that this will be a down year for the market.

In our Model Portfolios, we are currently 77% invested, but we’ll likely step up from this level if fundamental and technical models continue to improve.

Learn more about this financial newsletter at Jim Stack's Investech Market Analyst.

Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary